Olivier NEGRE, Ph.D.

Olivier NEGRE, Ph.D.
More than 15 years of experience in gene therapy
Date and Place of Birth:
Marriage status:
Address:
April 25, 1974, Narbonne, France
Married, 3 kids
18 Sargent St, Cambridge MA 02140, USA
Cell phone: +1 (617) 797-7352
E-mail : [email protected]
Green Card
AREAS OF
EXPERTISE
Biotechnology, gene and cell therapy, gene editing, haemoglobin, sickle cell disease, thalassemia, globin chain analysis, erythropoiesis, hematopoietic stem cells, transplantation, in
vivo studies, research and development, preclinical studies, clinical trials, analytical methods,
international team leader, project management, Radiation Safety Officer.
PROFESSIONAL EXPERIENCE
Since 2014:
Principal Scientist, Director Preclinical Research at bluebird bio Cambridge (MA), USA
Involvement in preclinical and clinical gene therapy programs for -thalassemia and sickle cell
disease. R&D projects focused on hematopoietic stem cell culture, transduction, gene editing
and transplantation. Member of the LentiGlobin Program team. International manager leading
teams in France and in the USA. Radiation Safety Officer.
2005:
Researcher, Senior Scientist, Team leader at bluebird bio France (formerly Genetix
Pharmaceuticals inc.).
Gene Therapy: research, preclinical development, clinical trial LentiGlobin.
Bluebird bio France. Institute for Emerging Diseases and Innovative Therapies (iMETI).
CEA, Fontenay-aux-Roses, France
2003:
Internship at Massachusetts Institute of Technology (10 weeks)
Philippe LEBOULCH’s Laboratory, division of Health Sciences Technology
Cambridge MA, USA.
2000:
Allocataire de Recherche (Ph.D. Program)
Laboratory of Gene Therapy, Inserm U733
Saint-Louis Hospital, Paris, France
Research in gene therapy of -hemoglobinopathies
1999:
Engineer at BioProtein Technologies.
R&D - Production of recombinant proteins.
Cochin Hospital, Paris, France
Project in collaboration with INRA
1998:
Engineer at INSERM U477 (immunology and auto-immunity)
Research - Cochin Hospital, Paris, France.
Study of the mechanism by witch macrophages protect themselves from oxygen and NO
radicals.
1
EDUCATION
2015:
Radiation Safety Officer (Harvard School of Public Health, Boston)
2010 :
Habilitation à l’expérimentation animale (Ecole Nationale Vétérinaire d’Alfort, niveau 1).
Certificate to manage animal studies ( Alfort Veterinary School)
2009:
Personne Comptente en Radioprotection. Certificate to manage experiments with
raioactives compounds. Institut National des Sciences et Techniques Nucléaires. Saclay,
France.
2006:
Ph.D. Thérapeutiques Biotechnologiques (Gene and Cell Therapy)
Paris 7 University, France
Supervisors: Pr Yves BEUZARD
Laboratoire de Thérapie Génique Hématopoïétique (Pr Philippe LEBOULCH), Inserm U733,
Institut Universitaire d’Hématologie, Saint-Louis Hospital, Paris
Thesis title: Gene Therapy of hemoglobinopathies – oncogenic safety of gene transfer and
expansion of genetically modified haematopoietic cells in vivo
2003:
Training period at Massachusetts Institute of Technology (10 weeks), Philippe
LEBOULCH’s laboratory, division of Health Sciences Technology, Cambridge, USA
2000:
Diplôme d’Etudes Approfondies: Thérapeutiques Biotechnologiques (Diploma of
Advanced Studies in Biotechnologies). Paris 7, Denis Diderot University, Paris, France.
Production of recombinant proteins and monoclonal antibodies to develop an
immunochromatographic assay for the diagnosis of Helicobacter infection.
1998 :
Engineering Degree in Biochemistry (Master of Science), Ecole Supérieure de Technologie
des Biomolécules de Bordeaux, France.
Seven month training period at Sanofi Recherche, Unité de Biologie Moléculaire du Gène (Dr.
Daniel Caput), Labège, France. Studies of proteins p73 and p53
PUBLICATIONS
Negre O, Eggimann AV, Beuzaerd Y, Ribeil JA, Bourget P, Borwornpinyo S, Hongeng S, Hacein-Bey S, Cavazzana M,
Leboulch P, Payen E.
Gene Therapy of the -hemoglobinopathies by Lentiviral Transfer of (A(T87Q))-Globin Gene.
Human Gene Therapy, 2016 Feb; 27(2):148-65
Negre O, Bartholomae C, Beuzard Y, Cavazzana M, Christiansen L, Courne C, Deichmann A, Denaro M, Dreuzy Ed,
Finer M, Fronza R, Gillet-Legrand B, Joubert C, Kutner R, Leboulch P, Maouche L, Paulard A, Pierciey FJ, Rothe M, Ryu
B, Schmidt M, Kalle Cv, Payen E, Veres G.
Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia
and Sickle Cell Disease.
Current Gene Therapy. 2015; 15(1):64-81
2
Arlet JB, Ribeil JA, Guillem F, Negre O, Hazoume A, Marcion G, Beuzard Y, Dussiot M, Moura IC, Demarest S, de
Beauchêne IC, Belaid-Choucair Z, Sevin M, Maciel TT, Auclair C, Leboulch P, Chretien S, Tchertanov L, Baudin-Creuza
V, Seigneuric R, Fontenay M, Garrido C, Hermine O, Courtois G.
HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia.
Nature. 2014 Aug 24.
Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, Grapton D, Paubelle E, Payen E, Beuzard Y, Leboulch P,
Ribeil JA, Arlet JB, Coté F, Courtois G, Ginzburg YZ, Daniel TO, Chopra R, Sung V, Hermine O, Moura IC.
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.
Nature Medicine. 2014 Apr;20(4):398-407
Tubsuwan A, Abed S, Deichmann A, Kardel MD, Bartholomä C, Cheung A, Negre O, Kadri Z, Fucharoen S, von Kalle
C, Payen E, Chrétien S, Schmidt M, Eaves CJ, Leboulch P, Maouche-Chrétien L.
Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells
derived from the same transplanted β-thalassemia patient.
Stem Cells. 2013 Sep;31(9):1785-94
Payen E, Colomb C, Negre O, Beuzard Y, Hehir K, Leboulch P.
Lentivirus vectors in β-thalassemia.
Methods Enzymol. 2012;507:109-24.
J.-B. Arlet, J.-A. Ribeil, A. Hazoume, O. Negre, C. Garido, G. Courtois, O. Hermine
Role of Hsp 70 in -thalassemia major ineffective erythropoiesis (in French)
La Revue de Médecine Interne. 33:S57. June 2012.
Negre O, Fusil F, Colomb C, Roth S, Gillet-Legrand B, Henri A, Beuzard Y, Bushman F, Leboulch P, Payen E.
Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid
expansion.
Blood. 2011 May 19;117(20):5321-31
Ronen K, Negre O, Roth S, Colomb C, Malani N, Denaro M, Brady T, Fusil F, Gillet-Legrand B, Hehir K, Beuzard Y,
Leboulch P, Down JD, Payen E, Bushman FD.
Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia.
Molecular Therapy 2011 Jul;19(7):1273-86.
Cavazzana Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K,
Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chrétien L, Bernaudin F, Girot R, Dorazio R, Mulder
GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chrétien S, Cartier N, Aubourg P,
Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P.
Transfusion independence and HMGA2 activation after gene therapy of human b-thalassemia
Nature 2010 Sep 16; 467(7313):318-22
Negre O, Fusil F, henri A, Villette JM, Leboulch P, Beuzard Y, Payen E.
Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Experimental Hematology. 2008 Apr ; 36(4):412-23
De Piedoue G, Maurisse R, Kuzniak I, Lopez B, Perrin A, Negre O, Leboulch P, Feugeas JP.
Improving gene replacement by intracellular formation of linear homologous DNA.
Journal of Gene Medicine. 2005 Jan 10, online
Ferret PJ, Soum E, Negre O, Fradelizi D.
Auto-protective redox buffering systems in stimulated macrophages.
BMC Immunology. 2002 Mar 12; 3 (1):3.
Ferret PJ, Soum E, Negre O, Wollman EE, Fradelizi D.
Protective effect of thioredoxin upon NO-mediated cell in jury in THP1 monocytic human cells.
Biochemical Journal. 2000 Mar 15; 346 Pt 3: 759-65.
3
CONTRIBUTION TO ORAL COMMUNICATIONS
M. Cavazzana, JA Ribeil, E. Payen, F. Suarez, O. Negre, Y. Beuzard, F. Touzot, R. Cavallesco, F. Lefrere, S. Chretien, P.
Bourget, F. Monpoux, C. Pondarre, B. Neven, F. Bushman, M. Schmidt, C. von Kalle, L. Sandler, S. Soni, B. Ryu, R.
Kutner, G. Veres, M. Finer, S. Blanche, O. Hermine, S. Hacein-Bey-Abina, P. Leboulch
Improving gene therapy for b-thalassemia major: initial results from study HGB-205
EHA annual meeting 2014, Milano, Italy
Olivier Negre, Emmanuel Payen, Yves Beuzard, Françoise Bernaudin, Troy Brady, Béatrix Gillet-Legrand, Céline
Courne, Anaïs Paulard, Stany Chretien, Gabor Veres, Mitch Finer, Frederic Bushman, Salima Hacein-Bey Abina, Marina
Cavazzana-Calvo, Philippe Leboulch
Long-term transfusion independence of a gene therapy -thalassemia patient.
Red Blood Cell and Iron meeting 2013, Guadeloupe, France
Negre O, and Leboulch P.
Five year outcome of lentiviral gene therapy for a human beta-thalassemia patient, lessons and prospects.
Hemoglobin Switching Meeting 2012, Monterey, USA
Olivier Negre, Keshet Ronen, Maria Denaro, Nirav Malani, Beatrix Gillet Legrand, Floriane Fusil, Kathleen Hehir,
Ronald Dorazio, Yves Beuzard, Philippe Leboulch, Julian D Down, Emmanuel Payen, Frederic D Bushman
Efficacy and safety assessment of a clinical-grade lentiviral-globin vector in a mouse model of Beta Thalassemia.
European School of Haematology (ESH) 2010, Cascais, Portugal
Negre O, Henri A, Dalle B, Leboulch P, Beuzard Y, Payen E.
Effet d’une érythropoïétine ancrée à la membrane cellulaire sur le développement des cellules érythroïdes.
Meeting of the French Society of Haematology 16-18 March 2003. Hématologie 9 (n° Hors série) , Abstract 03-21 :25
Dalle B, Payen E, Negre O, Henri A, Rouyer P, Beuzard Y, Leboulch P.
Expression du gène thérapeutique  T187Q dans les précurseurs érythroblastiques de patients drépanocytaires
homozygotes.
S. Meeting of the French Society of Haematology 16-18 mars 2003. Hématologie 9 (n°Hors série), Abstract 03-20 : 24
CONTRIBUTION TO POSTER COMMUNICATIONS
Melissa Bonner, Gretchen Lewis, Lauryn Christiansen, Dakota Campbell, Christopher Tipper, Amanda Hamel, Seema
Shah, Holly Horton, Olivier Negre, Gabor Veres, Philip Gregory
Staurosporine Increases Lentiviral Transduction of Human CD34+ cells
Annual meeting of the American Society of Gene and Cell Therapy (ASGCT) 2016, Washington DC, USA
Garrett Hefner, Melissa Bonner, Dakota Campbell, Lauryn Christiansen, John Pierciey, Wen Zhang, Gretchen Lewis,
Yegor Smurnyy, Amanda Hamel, Seema Shah, Holly Horton, Byoung Ryu, Kendrick Goss, Olivier Negre, Gabor Veres,
Christopher Horvath, Mitchell Finer, Philip Gregory
PGE2 Increases Lentiviral Transduction Efficiency of Human HSC
Annual meeting of the American Society of Gene and Cell Therapy (ASGCT) 2016, Washington DC, USA
Olivier Negre, Béatrix Gillet-Legrand , Kanit Bhukhai, Céline Courne, Anaïs Paulard, Yves Beuzard, Mitchell Finer,
Gabor Veres, Philippe Leboulch and Emmanuel Payen
Selection of genetically modified human and simian erythroid cells with a truncated erythropoietin receptor
Annual meeting of the American Society of Gene and Cell Therapy (ASGCT) 2014, Washington DC, USA
Olivier Negre, Cynthia Bartholoma, Céline Courne, Robert Kutner, Béatrix Gillet-Legrand, Anaïs Paulard, Byoung Ryu,
Maria Denaro, Christof von Kalle, Manfred Schmidt, Philippe Leboulch, Mitchell Finer, Emmanuel Payen and Gabor
Veres
Long term safety of clinical grade LentiGlobin vectors in -thalassemic and normal mice (update)
4
Annual meeting of the European Society of Gene and Cell Therapy (ESGCT) 2013, Madrid, Spain
Olivier Negre, Cynthia Bartholoma, Céline Courne, Robert Kutner, Béatrix Gillet-Legrand, Anaïs Paulard, Byoung Ryu,
Maria Denaro, Christof von Kalle, Manfred Schmidt, Philippe Leboulch, Mitchell Finer, Emmanuel Payen and Gabor
Veres
Long term efficacy of clinical grade LentiGlobin vectors in -thalassemic and normal mice
Annual meeting of the American Society of Gene and Cell Therapy (ASGCT) 2013, Salt Lake City, USA
Olivier Negre, Cynthia Bartholoma, Robert Kutner, Béatrix Gillet-Legrand, Céline Courne, Anaïs Paulard, Byoung Ryu,
Christophe Joubert, Anne-Laure Bauchet, Véronique Neuville, Charlotte Colomb, Yves Beuzard, Christof von Kalle,
Mitchell Finer, Manfred Schmidt, Philippe Leboulch, Gabor Veres, Emmanuel Payen
Large scale efficacy and safety study of two clinical grade LentiGlobin vectors in a mouse model of -thalassemia
Annual meeting of the European Society of Gene and Cell Therapy (ESGCT) 2012, Versailles, France
Floriane Fusil, Olivier Negre, Annie Henri, Yves Beuzard, Philippe Leboulch and Emmanuel Payen, Institut des Maladies
Emergentes et des Thérapies Innovantes, 18 route du Panorama, Fontenay aux Roses, France
Cure of a Mouse Model of Beta-Thalassemia by Gene Therapy with Limited Copy Number of Lentiviral Vector
Annual meeting of the American Society of Hematology (ASH) 2008, San Francisco, USA
Negre O, Fusil F, Henri A Leboulch P, Beuzard Y, Payen Emmanuel
Erythroid cell expansion induced by a truncated Epo receptor improves the lentiviral globin gene therapy in b
Thalassemic mice.
European School of Haematology (ESH) 2006, Cascais, Portugal
Negre O, Henri A, Dalle B, Leboulche P, Beuzard Y, Payen E
Etude de l’effet d’une érythropoïétine recombinante membranaire sur la prolifération et la différenciation des
cellules érythroïdes.
Meeting of the French Society of Gene and Cell Therapy (SFTCG) 2003, 19-20 June.
SCIENTIFIC SOCIETIES
Board of the French Society of Cell and Gene Therapy (SFTCG)
Member of the French Society for Red Blood Cells and Iron studies (CGRF)
Member of the European Society of Gene and Cell Therapy (ESGCT)
Member of the American Society of Gene and Cell Therapy (ASGCT)
Board ENSTBB Alumni – Biotech Engineer School – Bordeaux, France
5